Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A malignant disease of the T-lymphocytes in the bone marrow, thymus, and/or blood.
Biomarker and diagnostic research for T-cell leukemia has been reported in the published literature.
22 clinical trials registered, 16 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and biologic therapy. Pipeline includes 8 PHASE2, 6 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT01137825](https://clinicaltrials.gov/study/NCT01137825) |
Data assembled from 3 of 12 sources · Last updated Sep 17, 2026, 10:10 PM UTC
Common questions about T-cell leukemia
Registry of Older Patients With Cancer |
— |
UNC Lineberger Comprehensive Cancer Center |
RECRUITING |
[NCT05031897](https://clinicaltrials.gov/study/NCT05031897) | Two Step Haplo With Radiation Conditioning | PHASE2 | Thomas Jefferson University | RECRUITING |
[NCT07159620](https://clinicaltrials.gov/study/NCT07159620) | Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients | PHASE2 | The First Affiliated Hospital of Soochow University | RECRUITING |
[NCT07356245](https://clinicaltrials.gov/study/NCT07356245) | Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | PHASE2 | Jonathan Brammer | RECRUITING |
[NCT03829540](https://clinicaltrials.gov/study/NCT03829540) | CD4CAR for CD4+ Leukemia and Lymphoma | PHASE1 | Huda Salman | RECRUITING |
230 publications have been identified in PubMed for T-cell leukemia. Research spans Review / Meta-Analysis (35%), Basic Science / Preclinical (33%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 81 | 35% |
Laboratory research | 77 | 33% |
Clinical study results | 28 | 12% |
New treatment approaches | 24 | 10% |
Disease patterns and progression | 8 | 3% |
Testing and diagnosis research | 6 | 3% |
Other research | 3 | 1% |
Patient case studies | 3 | 1% |
Toyama K (2026). [PMID: 41605696](https://pubmed.ncbi.nlm.nih.gov/41605696/). *J Clin Exp Hematop*. [Basic Science / Preclinical]
Penter L (2026). [PMID: 41026928](https://pubmed.ncbi.nlm.nih.gov/41026928/). *Blood*. [Basic Science / Preclinical]
Itoh-Nakadai A (2026). [PMID: 41587986](https://pubmed.ncbi.nlm.nih.gov/41587986/). *Nat Commun*. [Gene Therapy / Novel Therapeutics]
Fetsch V (2026). [PMID: 41144759](https://pubmed.ncbi.nlm.nih.gov/41144759/). *Blood*. [Basic Science / Preclinical]
Torrent A (2026). [PMID: 40555197](https://pubmed.ncbi.nlm.nih.gov/40555197/). *Acta haematologica*. [Review / Meta-Analysis]
Wahnschaffe L (2026). [PMID: 41803141](https://pubmed.ncbi.nlm.nih.gov/41803141/). *Nat Commun*. [Basic Science / Preclinical]
Li F (2026). [PMID: 41806835](https://pubmed.ncbi.nlm.nih.gov/41806835/). *Cell*. [Gene Therapy / Novel Therapeutics]
Zhu Y (2026). [PMID: 41727472](https://pubmed.ncbi.nlm.nih.gov/41727472/). *Front Immunol*. [Review / Meta-Analysis]
Pinheiro PS (2026). [PMID: 42060270](https://pubmed.ncbi.nlm.nih.gov/42060270/). *JAMA Oncol*. [Diagnostic / Biomarker]
Guégan M (2026). [PMID: 41510799](https://pubmed.ncbi.nlm.nih.gov/41510799/). *Expert Rev Hematol*. [Review / Meta-Analysis]